<DOC>
	<DOC>NCT01193491</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety, determine the maximum tolerated dose (MTD) and schedule of IPI-493 in patients with hematologic malignancies.</brief_summary>
	<brief_title>Dose Escalation of IPI-493 in Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>&gt;/=18 years old ECOG 01 confirmed hematological malignancy refractory to available therapy or for which no therapy is available adequate hepatic, renal function active CNS malignancy prolonged QT interval significant GI/liver disease other serious concurrent illness or medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>AML</keyword>
	<keyword>CML</keyword>
	<keyword>MPD</keyword>
	<keyword>Client Proteins</keyword>
	<keyword>Hsp90</keyword>
</DOC>